$-106MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→The company lost $106M in 2025, more than the $74M it lost the year before. The losses are widening - check the Health chapter for how long the cash lasts.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$-115MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→The business consumed $115M of cash in 2025 after investment. Growth is being funded from the balance sheet, not from operations.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of -5% and ROCE of -9% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end
→The company holds $1.6B in cash against $700,000 of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The company's own capital grew from $-34M in 2023 to $3.3B. The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Shareholders received $216M in buybacks in 2023. Stock compensation issued $42M of new shares in the same year, offsetting 19% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→OKLO's return on capital is negative at -9.3% in 2025. The capital in the business is not yet earning anything back.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Insiders sold $106M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 16 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30